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Background: Novel therapies are being developed for patients with moderate to severe
asthma. These patients may have neutrophilic airway inflammation. Induced sputum is
commonly used as an endpoint in clinical trials of asthma therapies. We have performed
repeated induced sputum sampling in moderate to severe asthma patients to understand
the variability of cell counts, including neutrophils, and performed power calculations for
studies in this group of patients.
Methods: Nineteen patients with moderate to severe asthma with evidence of airflow obstruc-
tion (FEV1  80% predicted) and suboptimal control (ACQ  1) performed repeated induced
sputum separated by 1 month.
Results: The Ri of neutrophil percentage and absolute eosinophil count demonstrated good
(0.61) and moderate (0.56) repeatability respectively, but there was a poor level of agreement
for eosinophil percentage and absolute neutrophil counts. The within subject SD for sputum
neutrophil percentage was 15.8. In cross over studies, sample sizes of n Z 14 and n Z 54
are required to detect changes in neutrophil percentages by 20 and 10 % respectively at 90%
power.
Conclusions: Sputum neutrophil percentage has good reproducibility in patients with moderate
to severe asthma.
ª 2014 Elsevier Ltd. All rights reserved.)161 946 4050; fax: þ44 (0)161 946 1459.
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Induced sputum is a practical, non-invasive method of
measuring airway inflammation in asthma, with cell differ-
ential counts used to characterise the type of airway
inflammation present [1e3]. Sputum cell counts appear to
predict response to therapies, as patients with neutrophilic
airway inflammation respond poorly to corticosteroid ther-
apy [4], while patients with raised sputum eosinophil counts
appear to be a suitable target population for novel anti-
cytokine therapies that inhibit the eosinophil activity [5,6].
Induced sputum neutrophil and eosinophil counts may be
used to measure the effects of drugs in asthma, including
novel therapies [5e7]. The sample sizes required for such
studies are dependent on the reproducibility of sputum cell
counts. Previous sputum reproducibility studies in asthma
have enrolled patients with generally mild to moderate
asthma with relatively high eosinophil counts [2,8e10]. The
reproducibility of sputum measurements may be different
in persistently symptomatic patients with moderate to se-
vere asthma, who may display more evidence of neutro-
philic airway inflammation [3,4]. We report the
reproducibility of sputum neutrophil and eosinophil mea-
surements in patients with symptomatic moderate to se-
vere asthma; the data presented can be used for power
calculations for future clinical trials of novel anti-
inflammatory therapies in this population.
Methods
Nineteen adult patients (mean age 45.8 years; SD 13.4
years) with a physician diagnosis of asthma for at least 6
months and using ICS with a long acting beta agonist were
recruited. The mean (SD) Beclomethasone equivalent ICS
dose was 1342 (599.4). Patients were required to be lifelong
non-smokers, have pre-bronchodilator forced expiratory
volume in 1 s (FEV1)  80% predicted with reversibility of
12% or 200 mL to inhaled salbutamol and asthma control
questionnaire (ACQ-7) score  1. All patients provided
written informed consent. The study was approved by the
local research ethics committee.Table 1 Reproducibility of induced sputum measurements.
Visit 1 Visit 2
FEV1 (% Predicted) 67 (11) 72 (15)
Sputum total cell count
(x106/g sputum)b
2.19 (1.30, 3.71)a 2.72 (1.69, 4.
Sputum neutrophil (%) 51.6 (24.4) 56.5 (26.0)
Sputum eosinophil (%) 2.22 (0.95, 4.70)a 1.68 (0.75, 3.
Absolute sputum neutrophil
count (x 106/g sputum)
0.83 (0.42, 1.65)a 1.35 (0.70, 2.
Absolute sputum eosinophil
count (x 106/g sputum)
0.06 (0.03, 0.13)a 0.05 (0.02, 0.
Data are presented as mean (standard deviation).
SD Z standard deviation.
a denotes geometric mean (95% confidence interval).
b n Z 16.At Visit 1, the patients performed ACQ-7 score,
spirometry and reversibility to 200 mg salbutamol and
sputum induction. Induced sputum was repeated 1-month
later (Visit 2). Patients were required to have stable
asthma and have had no respiratory tract infections in the
last 4 weeks prior to both visits. Sputum was processed for
cytospin preparation and creation as previously described
[11]. Four hundred non-squamous cells were counted; ab-
solute cell counts and differential cell counts were
obtained.
Intraclass correlation coefficients (Ri) were calculated
to assess the degree of agreement between repeated
measurements using SPSS version 19. Reproducibility was
also analysed using the Bland-Altman method with 95%
limits of agreement. Power calculations were performed
using Statmate version 2 software.Results
The mean prebronchodilator FEV1 (SD) of the participants
was 67.2 (11.4) % predicted, with mean ACQ-7 scores (SD)
of 2.04 (0.74). The mean percentage neutrophil counts at
both visits were >50%, indicating a profile of neutrophilic
airway inflammation (Table 1). The Ri of neutrophil per-
centage (0.61) and absolute eosinophil count (0.56)
demonstrated good and moderate levels of agreement
respectively. Poor agreement was observed for eosinophil
percentage and absolute neutrophil counts. The group
mean difference for sputum neutrophil percentage was
relatively small (4.95), but the Bland-Altman limits of
agreement indicated that a large variability could be
observed within an individual sampled on different days.
Similarly, limits of agreement showed relatively large
variability for other measurements.
The within subject SD for sputum neutrophil percentage
was 15.8 which was used for power calculations; cross over
studies require sample sizes of nZ 14 and nZ 54 to detect
changes in neutrophil percentages by 20 and 10% respec-
tively at 90% power. Other within subject SD presented in
Table 1 can be similarly utilised.Mean difference
(limits of agreement)
Within
subject SD
Intraclass
correlation
coefficient (Ri)
4.92 (29.1, 19.2) 8.70 0.54
38)a 0.73 (11.9, 10.4) 4.02 0.18
4.95 (48.8, 39.0) 15.8 0.61
37)a 3.7 (18.5, 25.9) 8.00 0.28
59)a 0.81 (9.84, 8.21) 3.26 0.11
11)a 0.02 (0.52, 0.56) 0.20 0.56
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This study focused on the patients with evidence of airflow
obstruction (FEV1  80% predicted) and suboptimal control
(ACQ  1) despite treatment with ICS and LABA therapy;
neutrophil percentage was the most reproducible sputum
measurement in these patients. The reproducibility of
sputum measurements in this population may differ from
milder populations, as there may be more day-to-day
variation in more severe patients [12]. Furthermore, the
patients in this study had increased sputum neutrophil
counts which may alter reproducibility. Previous studies
reporting the reproducibility of sputum measurements have
focused on milder asthma populations without raised
neutrophil counts [2,8e10]. This may lead to better Ri
values due to more stable disease; for example Bacci et al.
[8] reported Ri Z 0.85 for sputum neutrophil percentage
and Spanevello et al. [9] reported Ri Z 0.75.
Previous asthma studies have reported reproducibility
over 1 week or less [2,8e10]. Clinical trials of novel anti-
inflammatory drugs often require a longer duration for
drug efficacy to be observed [5e7]. We purposefully
assessed reproducibility after 1 month, which may be ex-
pected to result in increased variability compared to
shorter time intervals.
The reproducibility of sputum neutrophils after 4 days in
moderate to severe atopic asthmatics was reported as
RiZ 0.61 [10]; this is identical to our result. Patients in the
current study had mean neutrophil percentage >50%, which
is greater than the neutrophil counts found in healthy
controls and mild asthma patients [1,3,4,9e11]. Neutro-
philic airway inflammation is a feature of a subgroup of
patients with severe asthma [3,4,7], and targeting neutro-
phils has been suggested as a therapeutic option for these
patients [7]. The power calculations presented here show
the sample sizes required for clinical trials using neutrophil
percentage as a primary endpoint.
Our study population were not required specifically to
demonstrate sputum eosinophilia. Only 5 of the 19 patients
had eosinophils >3%, a threshold that is often used
[1,5,13,14]. Novel anti-eosinophil therapies may be best
targeted against patients with a high degree of eosinophilic
inflammation [5,6], and the data reported here is not
representative of such patients. We found that sputum ab-
solute eosinophil counts were more reproducible than
eosinophil percentage; this may be due to a relatively low
sputum eosinophil percentage that lacks reproducibility.
Previous reproducibility studies in asthma patients with ev-
idence of eosinophilic inflammation have reported Ri values
>0.8 [8e10]; this suggests that sputum eosinophil percent-
ages aremore reproducible in patients with a greater degree
of eosinophilic inflammation. Simpson et al. [13] reported
reproducibility of induced sputum eosinophil counts after 1-
month in a similar asthma cohort to ours, but did not report
neutrophil counts. They reported moderate (Ri Z 0.538)
levels of agreement for eosinophil counts using a 3% cut-off
point. Our lower levels of agreement are probably due to
the low number of patients with eosinophils>3% leading to a
less robust estimate of reproducibility. We extend the work
of Simpson et al. by also reporting sputum neutrophil
reproducibility in patients with moderate to severe asthma.In summary, we show that sputum neutrophil percent-
ages have good reproducibility in patients with moderate to
severe asthma, and suggest that this measurement can be
used as an endpoint to assess novel anti-inflammatory
therapies in these patients.References
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